CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Moderna's Vaccine (mRNA-1273) Against the Novel Coronavirus SARS-CoV-2 |
| May 28, 2020 | May 2020 Bond Updates |
|
LUXEMBOURG, May 28, 2020 /PRNewswire/ -- CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO) for the supply of APIs, Drug Products & Pharmaceutical Packaging, announces the signing of an amendment to their existing manufacturing agreement with Moderna,... |
| View more at: https://www.prnewswire.com:443/news-releases/cordenpharma--moderna-extend-strategic-manufacturing-services-agreement-for-the-supply-of-lipid-excipients-to-be-used-in-modernas-vaccine-mrna-1273-against-the-novel-coronavirus-sars-cov-2-301066688.html |
| Related News |
|